Kirkland & Ellis advised Option Care Enterprises, Inc., on its definitive merger agreement with BioScrip, Inc. (NASDAQ: BIOS), announced today. The combination of two of the nation’s largest independent providers of home and alternate treatment site infusion therapy services is expected to create a leading provider with the national reach, comprehensive therapy offering and financial capacity to succeed in the attractive and growing home and alternate site infusion services segment of the $100 billion U.S. infusion market. Under the terms of the merger agreement, BioScrip will issue new shares to Option Care’s shareholder, which is owned by investment funds affiliated with Madison Dearborn Partners, LLC, and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) in an all-stock transaction.
Read the company press release
The Kirkland team was led by transactional partners Sanford Perl, Mark Fennell and Joydeep Dasmunshi, and associates Dan Hoppe, Brandon Knop and Curt Ostosh; debt finance partners Michael Wright and Brian Tweedie, and associate Kyle Gillen; capital markets partner Robert Goedert; and antitrust partner Matthew Reilly and associate Michael DeRita.